# ![@OzmosiHealth Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::1055982930.png) @OzmosiHealth Ozmosi

Ozmosi posts on X about more info, data, health, $xbi the most. They currently have [-----] followers and [---] posts still getting attention that total [-----] engagements in the last [--] hours.

### Engagements: [-----] [#](/creator/twitter::1055982930/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1055982930/c:line/m:interactions.svg)

- [--] Week [------] +8.90%
- [--] Month [------] -6.10%
- [--] Months [-------] +23%
- [--] Year [---------] +23%

### Mentions: [---] [#](/creator/twitter::1055982930/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1055982930/c:line/m:posts_active.svg)

- [--] Week [---] -5%
- [--] Month [---] +17%
- [--] Months [-----] +9.70%
- [--] Year [-----] -0.31%

### Followers: [-----] [#](/creator/twitter::1055982930/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1055982930/c:line/m:followers.svg)

- [--] Week [-----] +0.30%
- [--] Month [-----] +0.53%
- [--] Months [-----] +14%
- [--] Year [-----] +44%

### CreatorRank: [-------] [#](/creator/twitter::1055982930/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::1055982930/c:line/m:influencer_rank.svg)

### Social Influence

**Social category influence**
[stocks](/list/stocks)  57.14% [countries](/list/countries)  5.19% [cryptocurrencies](/list/cryptocurrencies)  3.57% [currencies](/list/currencies)  0.32% [technology brands](/list/technology-brands)  0.32% [finance](/list/finance)  0.32%

**Social topic influence**
[more info](/topic/more-info) #280, [data](/topic/data) 4.22%, [health](/topic/health) 3.25%, [$xbi](/topic/$xbi) 2.92%, [$ibb](/topic/$ibb) 2.92%, [$xph](/topic/$xph) 2.92%, [$pph](/topic/$pph) 2.92%, [canada](/topic/canada) 2.92%, [the first](/topic/the-first) 2.6%, [$cgtx](/topic/$cgtx) #15

**Top accounts mentioned or mentioned by**
[@wallstreet_dawg](/creator/undefined) [@megabyte48](/creator/undefined)

**Top assets mentioned**
[Cognition Therapeutics, Inc. (CGTX)](/topic/$cgtx) [Tenaya Therapeutics, Inc.  (TNYA)](/topic/$tnya) [Denali Therapeutics Inc. Common Stock (DNLI)](/topic/$dnli) [Nurix Therapeutics, Inc. (NRIX)](/topic/$nrix) [Immunocore Holdings Limited (IMCR)](/topic/$imcr) [Cullinan Management, Inc. (CGEM)](/topic/$cgem) [Kymera Therapeutics, Inc. (KYMR)](/topic/$kymr) [Relay Therapeutics, Inc. (RLAY)](/topic/$rlay) [Invivyd, Inc. (IVVD)](/topic/$ivvd) [Synthetify (SNY)](/topic/$sny) [Mirum Pharmaceuticals, Inc. Common Stock (MIRM)](/topic/$mirm) [Roivant Sciences Ltd. Common Shares (ROIV)](/topic/$roiv) [Coya Therapeutics, Inc. (COYA)](/topic/$coya) [Elevai Labs, Inc. (ELAB)](/topic/$elab) [Adlai Nortye Ltd (ANL)](/topic/$anl) [Xilio Therapeutics, Inc. (XLO)](/topic/$xlo) [4D Molecular Therapeutics Inc. (FDMT)](/topic/$fdmt) [MapLight Therapeutics, Inc (MPLT)](/topic/$mplt) [Zenas BioPharma, Inc. (ZBIO)](/topic/$zbio) [Atai Life Sciences B.V. (ATAI)](/topic/atai-life) [TG Therapeutics, Inc. (TGTX)](/topic/$tgtx) [Biogen Inc (BIIB)](/topic/$biib) [Sagimet Biosciences Inc. (SGMT)](/topic/$sgmt) [Sanofi (SNY)](/topic/sanofi) [Pfizer, Inc. (PFE)](/topic/$pfe) [Upstream Bio, Inc. (UPB)](/topic/$upb) [Viking Therapeutics, Inc (VKTX)](/topic/$vktx) [Harmony Biosciences Holdings, Inc. (HRMY)](/topic/$hrmy) [NeuroSense Therapeutics Ltd. (NRSN)](/topic/$nrsn) [Biomea Fusion, Inc. (BMEA)](/topic/$bmea) [Oric Pharmaceuticals, Inc. (ORIC)](/topic/$oric) [Annovis Bio Inc. (ANVS)](/topic/$anvs) [Werewolf Therapeutics, Inc. (HOWL)](/topic/$howl) [Incyte Corporation (INCY)](/topic/$incy) [Gain Therapeutics, Inc. (GANX)](/topic/$ganx) [Taysha Gene Therapies, Inc. (TSHA)](/topic/$tsha) [Mist (MIST)](/topic/$mist) [Exelixis Inc (EXEL)](/topic/$exel) [Jade Biosciences, Inc. (JBIO)](/topic/$jbio) [Viridian Therapeutics, Inc. Common Stock (VRDN)](/topic/$vrdn) [Actuate Therapeutics, Inc. (ACTU)](/topic/$actu) [Oruka Therapeutics, Inc. Common Stock (ORKA)](/topic/$orka) [Pasithea Therapeutics Corp. (KTTA)](/topic/$ktta) [C4 Therapeutics, Inc (CCCC)](/topic/$cccc) [Nasus Pharma Ltd (NSRX)](/topic/$nsrx) [Orange Swan Event (OSE)](/topic/$ose) [AB (prev. Newton) (AB)](/topic/$ab) [Amicus Therapeutics, Inc (FOLD)](/topic/$fold) [SuperRare (RARE)](/topic/$rare) [Merck & Co., Inc. (MRK)](/topic/$mrk) [Caribou Biosciences, Inc. (CRBU)](/topic/$crbu) [MiNK Therapeutics, Inc. (INKT)](/topic/$inkt) [Mineralys Therapeutics, Inc. (MLYS)](/topic/$mlys) [ALX Oncology Holdings Inc (ALXO)](/topic/$alxo) [IN8bio, Inc. (INAB)](/topic/$inab) [Arcellx, Inc. (ACLX)](/topic/$aclx) [Evommune, Inc. (EVMN)](/topic/$evmn) [OS Therapies Incorporated (OSTX)](/topic/$ostx)
### Top Social Posts
Top posts by engagements in the last [--] hours

"$MNMD up 45% today 🚀 as 20-year-old university student that made a $110 million profit with a one-month bet on Bed Bath & Beyond stock also mentions Mind Medicine Mind Medicine also with positive updates on their pipeline this summer:"  
[X Link](https://x.com/OzmosiHealth/status/1560267518337462273)  2022-08-18T14:08Z [----] followers, [--] engagements


"$ELAB Elevai Labs obtains exclusive license for two muscle loss prevention assets plans to develop in combination with GLP-1 obesity treatments. More Info: $XBI $IBB $XPH $PPH https://pryzm.ozmosi.com/product/11908 https://pryzm.ozmosi.com/product/11908"  
[X Link](https://x.com/OzmosiHealth/status/1785656049477009480)  2024-05-01T13:02Z [----] followers, [---] engagements


"$ELAB Elevai Labs obtains exclusive license for two muscle loss prevention assets to develop along with GLP-1 obesity treatments. More Info: $XBI $IBB $XPH $PPH https://pryzm.ozmosi.com/product/11908 https://pryzm.ozmosi.com/product/11908"  
[X Link](https://x.com/OzmosiHealth/status/1785667379038699669)  2024-05-01T13:47Z [----] followers, [---] engagements


"$ELAB Elevai Labs secures rights to two muscle loss prevention assets to be combined with GLP-1 obesity treatments. More Info: $XBI $IBB $XPH $PPH https://pryzm.ozmosi.com/product/11908 https://pryzm.ozmosi.com/product/11908"  
[X Link](https://x.com/OzmosiHealth/status/1785671150137376992)  2024-05-01T14:02Z [----] followers, [---] engagements


"$OCGN Ocugen Inc. lifts clinical hold on IND for OCU200 Phase [--] Trial. More Info: $XBI $IBB $XPH $PPH https://pryzm.ozmosi.com/product/25834 https://pryzm.ozmosi.com/product/25834"  
[X Link](https://x.com/OzmosiHealth/status/1843970207108517995)  2024-10-09T11:02Z [----] followers, [---] engagements


"$OCGN Ocugen reveals promising early results for OCU410 a new gene therapy for treating dry age-related macular degeneration. More Info: $XBI $IBB $XPH $PPH https://pryzm.ozmosi.com/product/27030 https://pryzm.ozmosi.com/product/27030"  
[X Link](https://x.com/OzmosiHealth/status/1858850741609525367)  2024-11-19T12:32Z [----] followers, [---] engagements


"$ARDX China has approved Tenapanor for treating hyperphosphatemia. More Info: $XBI $IBB $XPH $PPH https://pryzm.ozmosi.com/product/2151 https://pryzm.ozmosi.com/product/2151"  
[X Link](https://x.com/OzmosiHealth/status/1894727253168439735)  2025-02-26T12:32Z [----] followers, [---] engagements


"$IVA IVEVF PARIS:IVA Inventiva's study on lanifibranor treatment for MASLD/MASH patients & preclinical models published in Journal of Hepatology Reports. More Info: $XBI $IBB $XPH $PPH https://pryzm.ozmosi.com/product/19858 https://pryzm.ozmosi.com/product/19858"  
[X Link](https://x.com/OzmosiHealth/status/1940546604383326409)  2025-07-02T23:02Z [----] followers, [---] engagements


"$ABCL AbCellera releases Q2 [----] results & doses first participants in Phase [--] trial for ABCL635 treating Vasomotor Symptoms. More Info: $XBI $IBB $XPH $PPH https://pryzm.ozmosi.com/product/32498 https://pryzm.ozmosi.com/product/32498"  
[X Link](https://x.com/OzmosiHealth/status/1953554921460314396)  2025-08-07T20:32Z [----] followers, [----] engagements


"$RGNX Regenxbio presented Phase [--] Mucopolysaccharidosis II results on 2025-09-05 for Clemidsogene lanparvovec More Info: https://pryzm.ozmosi.com/product/25156 https://pryzm.ozmosi.com/product/25156"  
[X Link](https://x.com/OzmosiHealth/status/1965147509388353721)  2025-09-08T20:17Z [----] followers, [---] engagements


"$EVAX Evaxion Biotech announced they will present Phase [--] Melanoma results on 2025-10-17 for EVX-01 More Info: https://pryzm.ozmosi.com/product/25443 https://pryzm.ozmosi.com/product/25443"  
[X Link](https://x.com/OzmosiHealth/status/1978216503305531640)  2025-10-14T21:49Z [----] followers, [---] engagements


"$ANL +0.30% today as Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics More Info: https://pryzm.ozmosi.com/product/36415 https://pryzm.ozmosi.com/product/36415"  
[X Link](https://x.com/OzmosiHealth/status/1980992732127531190)  2025-10-22T13:40Z [----] followers, [---] engagements


"$VKTX Viking announced they will present P3 Type [--] DiabetesObesity results on 2025-11-08 for VK-2735 More Info: https://pryzm.ozmosi.com/product/25106 https://pryzm.ozmosi.com/product/25106"  
[X Link](https://x.com/anyuser/status/1981724735231672371)  2025-10-24T14:09Z [----] followers, [----] engagements


"$XLO +4.15% today as Xilio Therapeutics to Present Phase [--] Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting More Info: https://pryzm.ozmosi.com/product/23341 https://pryzm.ozmosi.com/product/23341"  
[X Link](https://x.com/OzmosiHealth/status/1983895820417085712)  2025-10-30T13:56Z [----] followers, [---] engagements


"$XLO Xilio Therapeutics announced they will present P2 Colorectal Cancer results on 2025-11-07 for Vilastobart More Info: https://pryzm.ozmosi.com/product/23341 https://pryzm.ozmosi.com/product/23341"  
[X Link](https://x.com/OzmosiHealth/status/1985363694251884810)  2025-11-03T15:09Z [----] followers, [---] engagements


"$NRIX -6.08% today as Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling More Info: https://pryzm.ozmosi.com/product/24725 https://pryzm.ozmosi.com/product/24725"  
[X Link](https://x.com/OzmosiHealth/status/1986836446175490154)  2025-11-07T16:41Z [----] followers, [---] engagements


"$IMCR Immunocore presented P1 Hepatitis B results on 2025-11-07 for IMC-I109V-101 More Info: https://pryzm.ozmosi.com/product/30448.0 https://pryzm.ozmosi.com/product/30448.0"  
[X Link](https://x.com/OzmosiHealth/status/1987954916992672026)  2025-11-10T18:46Z [----] followers, [---] engagements


"$NRIX Nurix Therapeutics presented P1 Oncology Solid Tumor Unspecified results on 2025-11-07 for NX-1607 More Info: https://pryzm.ozmosi.com/product/24725.0 https://pryzm.ozmosi.com/product/24725.0"  
[X Link](https://x.com/OzmosiHealth/status/1987954938232684634)  2025-11-10T18:46Z [----] followers, [---] engagements


"$XLO Xilio Therapeutics presented P1 Oncology Solid Tumor Unspecified results on 2025-11-07 for Efarindodekin alfa More Info: https://pryzm.ozmosi.com/product/26196.0 https://pryzm.ozmosi.com/product/26196.0"  
[X Link](https://x.com/OzmosiHealth/status/1987954973724852667)  2025-11-10T18:46Z [----] followers, [---] engagements


"🚀🚨 BIOPHARM CATALYST ALERT 📆 $IMMP Immutep will present Phase [--] Sarcoma Data for Eftilagimod alpha (LAG3 Analogue - Fusion Protein) tomorrow 👀"  
[X Link](https://x.com/OzmosiHealth/status/1988565530450764220)  2025-11-12T11:12Z [----] followers, [---] engagements


"$HRMY +0.64% today as Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation More Info: https://pryzm.ozmosi.com/product/1714 https://pryzm.ozmosi.com/product/1714"  
[X Link](https://x.com/OzmosiHealth/status/1992971046954094956)  2025-11-24T14:58Z [----] followers, [---] engagements


"$NRSN -1.40% today as NeuroSense Receives FDA Clearance to Initiate Pivotal Phase [--] Trial for PrimeC in ALS More Info: https://pryzm.ozmosi.com/product/28154 https://pryzm.ozmosi.com/product/28154"  
[X Link](https://x.com/OzmosiHealth/status/1993064759034282166)  2025-11-24T21:10Z [----] followers, [---] engagements


"$CGEM -6.60% today as Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049 a Novel FLT3xCD3 T Cell Engager in Relapsed/Refractory Acute Myeloid Leukemia More Info: https://pryzm.ozmosi.com/product/24765 https://pryzm.ozmosi.com/product/24765"  
[X Link](https://x.com/OzmosiHealth/status/1995519776974659828)  2025-12-01T15:46Z [----] followers, [---] engagements


"$VALN Valneva presented P2 Lyme Disease results on 2025-11-26 for VLA-15 More Info: https://pryzm.ozmosi.com/product/17682 https://pryzm.ozmosi.com/product/17682"  
[X Link](https://x.com/OzmosiHealth/status/1995577390865465772)  2025-12-01T19:35Z [----] followers, [---] engagements


"$BMEA -7.31% today as Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance Diabetes & Cardiovascular Disease (WCIRDC) More Info: https://pryzm.ozmosi.com/product/23569 https://pryzm.ozmosi.com/product/23569"  
[X Link](https://x.com/OzmosiHealth/status/1995617678950535180)  2025-12-01T22:15Z [----] followers, [----] engagements


"$ORIC Oric announced they will present P1 Non-Small-Cell Lung Cancer results on 2025-12-05 for Enozertinib More Info: https://pryzm.ozmosi.com/product/25434 https://pryzm.ozmosi.com/product/25434"  
[X Link](https://x.com/OzmosiHealth/status/1995962724619088045)  2025-12-02T21:06Z [----] followers, [---] engagements


"$ANVS Annovis Bio announced they will present Unknown Parkinson's Disease results on 2025-12-05 for Buntanetap More Info: https://pryzm.ozmosi.com/product/21508 https://pryzm.ozmosi.com/product/21508"  
[X Link](https://x.com/OzmosiHealth/status/1996664503321104779)  2025-12-04T19:34Z [----] followers, [---] engagements


"$ORIC Oric presented P1 Oncology Solid Tumor Unspecified results on 2025-12-04 for Enozertinib More Info: https://pryzm.ozmosi.com/product/25434 https://pryzm.ozmosi.com/product/25434"  
[X Link](https://x.com/OzmosiHealth/status/1997043237186363784)  2025-12-05T20:39Z [----] followers, [---] engagements


"$NRIX Nurix Therapeutics presented P1 Waldenstrom Macroglobulinemia results on 2025-12-08 for Bexobrutideg More Info: https://pryzm.ozmosi.com/product/24726 https://pryzm.ozmosi.com/product/24726"  
[X Link](https://x.com/OzmosiHealth/status/1998503278078738856)  2025-12-09T21:21Z [----] followers, [---] engagements


"$BRNS +7.75% today as Barinthus Bio Announces Update on Phase [--] AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease More Info: https://pryzm.ozmosi.com/product/27012 https://pryzm.ozmosi.com/product/27012"  
[X Link](https://x.com/OzmosiHealth/status/1998765333167931719)  2025-12-10T14:42Z [----] followers, [---] engagements


"$KYMR -2.48% today as Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621 a First-in-Class Oral STAT6 Degrader for the Treatment of Atopic Dermatitis More Info: https://pryzm.ozmosi.com/product/32322 https://pryzm.ozmosi.com/product/32322"  
[X Link](https://x.com/OzmosiHealth/status/1999171716170334272)  2025-12-11T17:37Z [----] followers, [---] engagements


"$DERM Journey Medical presented P1 Rosacea results on 2025-12-10 for DFD-29 More Info: https://pryzm.ozmosi.com/product/25524 https://pryzm.ozmosi.com/product/25524"  
[X Link](https://x.com/OzmosiHealth/status/1999185888710889879)  2025-12-11T18:33Z [----] followers, [---] engagements


"$TNYA -2.50% today as Tenaya Therapeutics Reports Positive Interim Data from Cohort [--] of RIDGE-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC More Info: https://pryzm.ozmosi.com/product/25601 https://pryzm.ozmosi.com/product/25601"  
[X Link](https://x.com/OzmosiHealth/status/1999238024924741642)  2025-12-11T22:01Z [----] followers, [---] engagements


"$TNYA -2.50% today as Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy More Info: https://pryzm.ozmosi.com/product/26351 https://pryzm.ozmosi.com/product/26351"  
[X Link](https://x.com/OzmosiHealth/status/1999238032042430516)  2025-12-11T22:01Z [----] followers, [---] engagements


"$RLAY +3.98% today as Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS [----] More Info: https://pryzm.ozmosi.com/product/25143 https://pryzm.ozmosi.com/product/25143"  
[X Link](https://x.com/OzmosiHealth/status/1999508877306446165)  2025-12-12T15:57Z [----] followers, [---] engagements


"$TNYA Tenaya Therapeutics presented P1 Arrhythmogenic Right Ventricular Dysplasia results on 2025-12-11 for TN-401 More Info: https://pryzm.ozmosi.com/product/25601 https://pryzm.ozmosi.com/product/25601"  
[X Link](https://x.com/OzmosiHealth/status/1999549501082603879)  2025-12-12T18:38Z [----] followers, [---] engagements


"$RLAY Relay Therapeutics presented P1 Breast Cancer results on 2025-12-12 for Zovegalisib More Info: https://pryzm.ozmosi.com/product/25143 https://pryzm.ozmosi.com/product/25143"  
[X Link](https://x.com/OzmosiHealth/status/2000675104414453764)  2025-12-15T21:11Z [----] followers, [---] engagements


"$FDMT 4D Molecular presented P1 Cystic Fibrosis results on 2025-12-17 for Plencifgene parvec More Info: https://pryzm.ozmosi.com/product/29769 https://pryzm.ozmosi.com/product/29769"  
[X Link](https://x.com/OzmosiHealth/status/2001766207364440291)  2025-12-18T21:27Z [----] followers, [---] engagements


"$HOWL Werewolf Therapeutics announced they will present P1 Oncology Solid Tumor Unspecified results in 1H26 for WTX-124 More Info: https://pryzm.ozmosi.com/product/25073 https://pryzm.ozmosi.com/product/25073"  
[X Link](https://x.com/OzmosiHealth/status/2002094801206890922)  2025-12-19T19:12Z [----] followers, [---] engagements


"$HOWL Werewolf Therapeutics announced they will present P1 Oncology Solid Tumor Unspecified results in 1H26 for WTX-330 More Info: https://pryzm.ozmosi.com/product/25074 https://pryzm.ozmosi.com/product/25074"  
[X Link](https://x.com/OzmosiHealth/status/2002094807737397345)  2025-12-19T19:12Z [----] followers, [---] engagements


"$IVVD as Invivyd Announces Initiation of DECLARATION Clinical Trial a Phase [--] Placebo-Controlled Pivotal Study of VYD2311 a Vaccine-Alternative Antibody to Prevent COVID More Info: https://pryzm.ozmosi.com/product/33169 https://pryzm.ozmosi.com/product/33169"  
[X Link](https://x.com/OzmosiHealth/status/2003664928255934759)  2025-12-24T03:11Z [----] followers, [---] engagements


"$ANL +nan% today Alert Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China More Info: https://pryzm.ozmosi.com/product/37014 https://pryzm.ozmosi.com/product/37014"  
[X Link](https://x.com/OzmosiHealth/status/2005672917485383780)  2025-12-29T16:11Z [----] followers, [---] engagements


"$BCAB Alert BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) More Info: https://pryzm.ozmosi.com/product/20435 https://pryzm.ozmosi.com/product/20435"  
[X Link](https://x.com/OzmosiHealth/status/2006365252246507734)  2025-12-31T14:02Z [----] followers, [---] engagements


"$MPLT MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer's Disease Psychosis More Info: https://pryzm.ozmosi.com/product/31046 https://pryzm.ozmosi.com/product/31046"  
[X Link](https://x.com/OzmosiHealth/status/2008177427458183365)  2026-01-05T14:03Z [----] followers, [---] engagements


"$INCY Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi/Minjuvi) as a First-line Treatment for Diffuse Large B-Cell Lymphoma More Info: https://pryzm.ozmosi.com/product/18517 https://pryzm.ozmosi.com/product/18517"  
[X Link](https://x.com/OzmosiHealth/status/2008177430738153976)  2026-01-05T14:03Z [----] followers, [---] engagements


"$GHRS GH Research Announces FDA Lifts Clinical Hold on GH001 Clearing Path for Global Phase [--] Initiation in [----] More Info: https://pryzm.ozmosi.com/product/26166 https://pryzm.ozmosi.com/product/26166"  
[X Link](https://x.com/OzmosiHealth/status/2008177472899338349)  2026-01-05T14:03Z [----] followers, [---] engagements


"$APGE Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777) its Potentially Best-in-Class Anti-IL-13 Antibody in Patients with Mild-to-Moderate Asthma and Highlights [----] Anticipated Milestones and Outlook More Info: https://pryzm.ozmosi.com/product/31038 https://pryzm.ozmosi.com/product/31038"  
[X Link](https://x.com/OzmosiHealth/status/2008539735644598329)  2026-01-06T14:02Z [----] followers, [---] engagements


"$GANX Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287 More Info: https://pryzm.ozmosi.com/product/23956 https://pryzm.ozmosi.com/product/23956"  
[X Link](https://x.com/OzmosiHealth/status/2008539741399249307)  2026-01-06T14:02Z [----] followers, [---] engagements


"$AKBA Akebia Therapeutics Announces First Patient Dosed in Phase [--] Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS) More Info: https://pryzm.ozmosi.com/product/19874 https://pryzm.ozmosi.com/product/19874"  
[X Link](https://x.com/OzmosiHealth/status/2008539749674611001)  2026-01-06T14:02Z [----] followers, [---] engagements


"$TSHA Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome More Info: https://pryzm.ozmosi.com/product/26042 https://pryzm.ozmosi.com/product/26042"  
[X Link](https://x.com/OzmosiHealth/status/2008539775750599119)  2026-01-06T14:02Z [----] followers, [---] engagements


"$MIST Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency More Info: https://pryzm.ozmosi.com/product/825 https://pryzm.ozmosi.com/product/825"  
[X Link](https://x.com/OzmosiHealth/status/2008539778359455774)  2026-01-06T14:02Z [----] followers, [---] engagements


"$TIL Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco More Info: https://pryzm.ozmosi.com/product/24624 https://pryzm.ozmosi.com/product/24624"  
[X Link](https://x.com/OzmosiHealth/status/2008539783740747957)  2026-01-06T14:02Z [----] followers, [---] engagements


"$VERA -1.12% today Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy More Info: https://pryzm.ozmosi.com/product/2843 https://pryzm.ozmosi.com/product/2843"  
[X Link](https://x.com/OzmosiHealth/status/2008902146272747607)  2026-01-07T14:02Z [----] followers, [---] engagements


"$EXEL +3.09% today Exelixis and Natera to Collaborate on STELLAR-316 a Phase [--] Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer More Info: https://pryzm.ozmosi.com/product/19713 https://pryzm.ozmosi.com/product/19713"  
[X Link](https://x.com/OzmosiHealth/status/2008902168749953421)  2026-01-07T14:02Z [----] followers, [---] engagements


"$GNLX Genelux announced they will present P3 Ovarian Cancer results in 2H26 for Olvimulogene nanivacirepvec More Info: https://pryzm.ozmosi.com/product/21639 https://pryzm.ozmosi.com/product/21639"  
[X Link](https://x.com/OzmosiHealth/status/2008930697730523175)  2026-01-07T15:56Z [----] followers, [---] engagements


"$JBIO Jade Biosciences announced they will present P1 Healthy Volunteers results in 1H26 for JADE-101 More Info: https://pryzm.ozmosi.com/product/34694 https://pryzm.ozmosi.com/product/34694"  
[X Link](https://x.com/OzmosiHealth/status/2008930700901433540)  2026-01-07T15:56Z [----] followers, [--] engagements


"$JBIO Jade Biosciences announced they will present P2 IgA Nephropathy results in YE27 for JADE-101 More Info: https://pryzm.ozmosi.com/product/34694 https://pryzm.ozmosi.com/product/34694"  
[X Link](https://x.com/OzmosiHealth/status/2008930703547977814)  2026-01-07T15:56Z [----] followers, [---] engagements


"$NMRA Neumora announced they will present P3 Depressive Disorder Major results in 2Q26 for Navacaprant More Info: https://pryzm.ozmosi.com/product/21674 https://pryzm.ozmosi.com/product/21674"  
[X Link](https://x.com/OzmosiHealth/status/2008930706605633600)  2026-01-07T15:56Z [----] followers, [---] engagements


"$ZBIO Zenas presented P3 IgG4-related Disease results on 2026-01-05 for Obexelimab More Info: https://pryzm.ozmosi.com/product/17691 https://pryzm.ozmosi.com/product/17691"  
[X Link](https://x.com/OzmosiHealth/status/2008930714566479894)  2026-01-07T15:56Z [----] followers, [---] engagements


"$TSHA Taysha Gene Therapies announced they will present P1 Rett Syndrome results in 1H26 for Lonimecgene Renparvovec More Info: https://pryzm.ozmosi.com/product/26042 https://pryzm.ozmosi.com/product/26042"  
[X Link](https://x.com/OzmosiHealth/status/2008966940274966533)  2026-01-07T18:20Z [----] followers, [---] engagements


"$VRDN Viridian Therapeutics announced they will present P1 Healthy Volunteers results in 2H26 for VRDN-008 More Info: https://pryzm.ozmosi.com/product/32196 https://pryzm.ozmosi.com/product/32196"  
[X Link](https://x.com/OzmosiHealth/status/2008966943697469934)  2026-01-07T18:20Z [----] followers, [---] engagements


"$GANX GAIN Therapeutics presented P1 Parkinson's Disease results on 2026-01-06 for GT-02287 More Info: https://pryzm.ozmosi.com/product/23956 https://pryzm.ozmosi.com/product/23956"  
[X Link](https://x.com/OzmosiHealth/status/2008966973963554950)  2026-01-07T18:20Z [----] followers, [---] engagements


"$RNAZ TRANSCODE THERAPEUTICS presented P0 Glioblastoma results on 2026-01-06 for TTX-MC138 More Info: https://pryzm.ozmosi.com/product/26544 https://pryzm.ozmosi.com/product/26544"  
[X Link](https://x.com/OzmosiHealth/status/2008966987678986751)  2026-01-07T18:20Z [----] followers, [---] engagements


"$RANI Rani Therapeutics Initiates Phase [--] Study of RT-114 RaniPill for the Treatment of Obesity in Collaboration with ProGen More Info: https://pryzm.ozmosi.com/product/33131 https://pryzm.ozmosi.com/product/33131"  
[X Link](https://x.com/OzmosiHealth/status/2009264511946309675)  2026-01-08T14:02Z [----] followers, [---] engagements


"$ATAI ATAI Life Sciences announced they will present P2 Depressive Disorder Treatment-Resistant results in 2H26 for VLS-01 More Info: https://pryzm.ozmosi.com/product/25732 https://pryzm.ozmosi.com/product/25732"  
[X Link](https://x.com/OzmosiHealth/status/2009691747149066731)  2026-01-09T18:20Z [----] followers, [---] engagements


"$ATAI ATAI Life Sciences announced they will present P2 Depressive Disorder Treatment-Resistant results in 4Q26 for BPL-003 More Info: https://pryzm.ozmosi.com/product/25522 https://pryzm.ozmosi.com/product/25522"  
[X Link](https://x.com/OzmosiHealth/status/2009691749573362093)  2026-01-09T18:20Z [----] followers, [---] engagements


"$ATAI ATAI Life Sciences announced they will present P2 Phobia Social results in 1Q26 for EMP-01 More Info: https://pryzm.ozmosi.com/product/26483 https://pryzm.ozmosi.com/product/26483"  
[X Link](https://x.com/OzmosiHealth/status/2009691752354197712)  2026-01-09T18:20Z [----] followers, [---] engagements


"$TRDA Entrada Therapeutics announced they will present P2 Muscular Dystrophy Duchenne results in 2Q26 for ENTR-601-44 More Info: https://pryzm.ozmosi.com/product/25129 https://pryzm.ozmosi.com/product/25129"  
[X Link](https://x.com/OzmosiHealth/status/2009691785367572966)  2026-01-09T18:20Z [----] followers, [---] engagements


"$ACRV Acrivon Therapeutics presented P1 Oncology Solid Tumor Unspecified results on 2026-01-08 for ACR-2316 More Info: https://pryzm.ozmosi.com/product/31119 https://pryzm.ozmosi.com/product/31119"  
[X Link](https://x.com/OzmosiHealth/status/2009691819085574186)  2026-01-09T18:20Z [----] followers, [---] engagements


"$ELVN Enliven Therapeutics presented P1 Chronic Myeloid Leukemia results on 2026-01-08 for ELVN-001 More Info: https://pryzm.ozmosi.com/product/25409 https://pryzm.ozmosi.com/product/25409"  
[X Link](https://x.com/OzmosiHealth/status/2009691830393434320)  2026-01-09T18:20Z [----] followers, [---] engagements


"$NRIX Nurix Therapeutics Outlines [----] Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases More Info: https://pryzm.ozmosi.com/product/24726 https://pryzm.ozmosi.com/product/24726"  
[X Link](https://x.com/OzmosiHealth/status/2010714095889346959)  2026-01-12T14:02Z [----] followers, [---] engagements


"$ACTU Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase [--] Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI [----] More Info: https://pryzm.ozmosi.com/product/22019 https://pryzm.ozmosi.com/product/22019"  
[X Link](https://x.com/OzmosiHealth/status/2010714107109154859)  2026-01-12T14:02Z [----] followers, [---] engagements


"$HRMY Harmony Biosciences Guides to Over $1 Billion in WAKIX Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation More Info: https://pryzm.ozmosi.com/product/1714 https://pryzm.ozmosi.com/product/1714"  
[X Link](https://x.com/OzmosiHealth/status/2010714109667606875)  2026-01-12T14:02Z [----] followers, [---] engagements


"$CABA IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms More Info: https://pryzm.ozmosi.com/product/27425 https://pryzm.ozmosi.com/product/27425"  
[X Link](https://x.com/OzmosiHealth/status/2010714116193911221)  2026-01-12T14:02Z [----] followers, [---] engagements


"$CNTB Connect Biopharma Highlights New Mechanism of Action Data for Rademikibart and Outlines Priorities for [----] More Info: https://pryzm.ozmosi.com/product/19365 https://pryzm.ozmosi.com/product/19365"  
[X Link](https://x.com/OzmosiHealth/status/2010714138126029005)  2026-01-12T14:03Z [----] followers, [---] engagements


"$CLNN Clene Announces Additional CNM-Au8 Biomarker Data Supporting Potential NDA Filing for Upcoming In-Person FDA Meeting More Info: https://pryzm.ozmosi.com/product/20186 https://pryzm.ozmosi.com/product/20186"  
[X Link](https://x.com/OzmosiHealth/status/2010714152373997879)  2026-01-12T14:03Z [----] followers, [---] engagements


"$CGON CG Oncology announced they will present P3 Muscle CancerBladder Cancer results in 1H26 for Cretostimogene grenadenorepvec More Info: https://pryzm.ozmosi.com/product/17148 https://pryzm.ozmosi.com/product/17148"  
[X Link](https://x.com/OzmosiHealth/status/2010812148201767311)  2026-01-12T20:32Z [----] followers, [---] engagements


"$IMCR Immunocore announced they will present P1 Oncology Solid Tumor Unspecified results in 2H26 for IMC-P115C More Info: https://pryzm.ozmosi.com/product/32540 https://pryzm.ozmosi.com/product/32540"  
[X Link](https://x.com/OzmosiHealth/status/2010812154090541540)  2026-01-12T20:32Z [----] followers, [---] engagements


"$IMCR Immunocore announced they will present P1 Ovarian CancerNon-Small-Cell Lung Cancer results in 2H26 for Brenetafusp More Info: https://pryzm.ozmosi.com/product/22989 https://pryzm.ozmosi.com/product/22989"  
[X Link](https://x.com/OzmosiHealth/status/2010812156703621416)  2026-01-12T20:32Z [----] followers, [---] engagements


"$IMCR Immunocore announced they will present P3 Melanoma results in 2H26 for Tebentafusp More Info: https://pryzm.ozmosi.com/product/11241 https://pryzm.ozmosi.com/product/11241"  
[X Link](https://x.com/OzmosiHealth/status/2010812159866065108)  2026-01-12T20:32Z [----] followers, [---] engagements


"$INSM Insmed announced they will present P2 Hidradenitis Suppurativa results in 2Q26 for Brensocatib More Info: https://pryzm.ozmosi.com/product/14505 https://pryzm.ozmosi.com/product/14505"  
[X Link](https://x.com/OzmosiHealth/status/2010812162391019821)  2026-01-12T20:32Z [----] followers, [---] engagements


"$TNYA Tenaya Therapeutics announced they will present P1 Arrhythmogenic Right Ventricular Dysplasia results in 1H26 for TN-401 More Info: https://pryzm.ozmosi.com/product/25601 https://pryzm.ozmosi.com/product/25601"  
[X Link](https://x.com/OzmosiHealth/status/2010812175703826522)  2026-01-12T20:32Z [----] followers, [---] engagements


"$TNYA Tenaya Therapeutics announced they will present P1 Cardiomyopathy Hypertrophic results in 1H26 for TN-201 More Info: https://pryzm.ozmosi.com/product/26351 https://pryzm.ozmosi.com/product/26351"  
[X Link](https://x.com/OzmosiHealth/status/2010812178291704237)  2026-01-12T20:32Z [----] followers, [---] engagements


"$LXEO Lexeo Therapeutics presented P1 Arrhythmogenic Cardiomyopathies results on 2026-01-12 for LX-2020 More Info: https://pryzm.ozmosi.com/product/30483 https://pryzm.ozmosi.com/product/30483"  
[X Link](https://x.com/OzmosiHealth/status/2011141279217045955)  2026-01-13T18:20Z [----] followers, [---] engagements


"$ORKA Oruka Therapeutics presented P1 Healthy Volunteers results on 2026-01-12 for ORKA-002 More Info: https://pryzm.ozmosi.com/product/34383 https://pryzm.ozmosi.com/product/34383"  
[X Link](https://x.com/OzmosiHealth/status/2011141288872271877)  2026-01-13T18:20Z [----] followers, [---] engagements


"$KTTA Pasithea Therapeutics announced they will present P1 Neurofibroma Plexiform results in 2H26 for PAS-004 More Info: https://pryzm.ozmosi.com/product/25828 https://pryzm.ozmosi.com/product/25828"  
[X Link](https://x.com/OzmosiHealth/status/2011503632571908145)  2026-01-14T18:20Z [----] followers, [---] engagements


"$ANRO Alto Neuroscience presented P2 AnhedoniaDepressive Disorder Major results on 2026-01-13 for ALTO-203 More Info: https://pryzm.ozmosi.com/product/27727 https://pryzm.ozmosi.com/product/27727"  
[X Link](https://x.com/OzmosiHealth/status/2011503638024421449)  2026-01-14T18:20Z [----] followers, [---] engagements


"$CCCC C4 Therapeutics announced they will present P2 Multiple Myeloma results in 2H27 for Cemsidomide More Info: https://pryzm.ozmosi.com/product/21073 https://pryzm.ozmosi.com/product/21073"  
[X Link](https://x.com/OzmosiHealth/status/2011865984848838712)  2026-01-15T18:20Z [----] followers, [---] engagements


"$NBIX Neurocrine presented P2 Tardive Dyskinesia results on 2026-01-15 for Valbenazine More Info: https://pryzm.ozmosi.com/product/2327 https://pryzm.ozmosi.com/product/2327"  
[X Link](https://x.com/OzmosiHealth/status/2012228369782583797)  2026-01-16T18:20Z [----] followers, [---] engagements


"$GMAB Genmab Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase [--] EPCORE DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) More Info: https://pryzm.ozmosi.com/product/21245 https://pryzm.ozmosi.com/product/21245"  
[X Link](https://x.com/OzmosiHealth/status/2012269201302634931)  2026-01-16T21:02Z [----] followers, [---] engagements


"$DYN Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type [--] More Info: https://pryzm.ozmosi.com/product/26167 https://pryzm.ozmosi.com/product/26167"  
[X Link](https://x.com/OzmosiHealth/status/2013613179210018829)  2026-01-20T14:02Z [----] followers, [---] engagements


"$LTRN Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas More Info: https://pryzm.ozmosi.com/product/26464 https://pryzm.ozmosi.com/product/26464"  
[X Link](https://x.com/OzmosiHealth/status/2013613183030927625)  2026-01-20T14:02Z [----] followers, [---] engagements


"$NSRX Nasus Pharma Announces Positive Interim Results from Phase [--] Clinical Study of NS002 Intranasal Epinephrine Powder More Info: https://pryzm.ozmosi.com/product/36910 https://pryzm.ozmosi.com/product/36910"  
[X Link](https://x.com/OzmosiHealth/status/2013613186747113598)  2026-01-20T14:02Z [----] followers, [---] engagements


"$ACTU Actuate Therapeutics Announces Plans to Expand Clinical Pipeline Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers More Info: https://pryzm.ozmosi.com/product/22019 https://pryzm.ozmosi.com/product/22019"  
[X Link](https://x.com/OzmosiHealth/status/2013975502382633267)  2026-01-21T14:02Z [----] followers, [---] engagements


"$GMAB Genmab Announces Net Sales of DARZALEX (daratumumab) for [----] More Info: https://pryzm.ozmosi.com/product/3879 https://pryzm.ozmosi.com/product/3879"  
[X Link](https://x.com/OzmosiHealth/status/2013975505012421053)  2026-01-21T14:02Z [----] followers, [---] engagements


"$ARTV Artiva Biotherapeutics Announces Upcoming Presentations at the [----] Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL More Info: https://pryzm.ozmosi.com/product/23411 https://twitter.com/i/web/status/2013975510259568933 https://pryzm.ozmosi.com/product/23411 https://twitter.com/i/web/status/2013975510259568933"  
[X Link](https://x.com/OzmosiHealth/status/2013975510259568933)  2026-01-21T14:02Z [----] followers, [---] engagements


"$NSRX Nasus Pharma presented P2 Anaphylaxis results on 2026-01-20 for FMXIN-002 More Info: https://pryzm.ozmosi.com/product/36910 https://pryzm.ozmosi.com/product/36910"  
[X Link](https://x.com/OzmosiHealth/status/2014040366257955046)  2026-01-21T18:20Z [----] followers, [---] engagements


"$OSE OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) More Info: https://pryzm.ozmosi.com/product/18126 https://pryzm.ozmosi.com/product/18126"  
[X Link](https://x.com/OzmosiHealth/status/2014081194363854854)  2026-01-21T21:02Z [----] followers, [---] engagements


"$TARA Protara Therapeutics announced they will present P2 Muscle CancerBladder Cancer results on 2026-02-27 for TARA-002 More Info: https://pryzm.ozmosi.com/product/23637 https://pryzm.ozmosi.com/product/23637"  
[X Link](https://x.com/OzmosiHealth/status/2014765087178084485)  2026-01-23T18:20Z [----] followers, [---] engagements


"$MIST Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST (etripamil) Nasal Spray the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) More Info: https://pryzm.ozmosi.com/product/825 https://pryzm.ozmosi.com/product/825"  
[X Link](https://x.com/OzmosiHealth/status/2015787483188089252)  2026-01-26T14:02Z [----] followers, [---] engagements


"$NERV Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia on February [--] [----] More Info: https://pryzm.ozmosi.com/product/16270 https://pryzm.ozmosi.com/product/16270"  
[X Link](https://x.com/OzmosiHealth/status/2015787486384185662)  2026-01-26T14:02Z [----] followers, [---] engagements


"$TGTX TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum More Info: https://pryzm.ozmosi.com/product/8349 https://pryzm.ozmosi.com/product/8349"  
[X Link](https://x.com/OzmosiHealth/status/2016149829421039952)  2026-01-27T14:02Z [----] followers, [---] engagements


"$SRPT Sarepta presented P3 Muscular Dystrophy Duchenne results on 2026-01-26 for Delandistrogene moxeparvovec More Info: https://pryzm.ozmosi.com/product/25071 https://pryzm.ozmosi.com/product/25071"  
[X Link](https://x.com/OzmosiHealth/status/2016214660245291452)  2026-01-27T18:20Z [----] followers, [---] engagements


"$BIIB Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus a Disease With No Targeted Treatment Options More Info: https://pryzm.ozmosi.com/product/17141 https://pryzm.ozmosi.com/product/17141"  
[X Link](https://x.com/OzmosiHealth/status/2016512174957724089)  2026-01-28T14:02Z [----] followers, [---] engagements


"$TGTX TG Therapeutics announced they will present P2 Multiple Sclerosis results on 2026-02-05 for Ublituximab More Info: https://pryzm.ozmosi.com/product/8349 https://pryzm.ozmosi.com/product/8349"  
[X Link](https://x.com/OzmosiHealth/status/2016577041353888083)  2026-01-28T18:20Z [----] followers, [----] engagements


"$CRDF Cardiff Oncology presented P2 Colorectal Cancer results on 2026-01-27 for FOLFOX More Info: https://pryzm.ozmosi.com/product/19487 https://pryzm.ozmosi.com/product/19487"  
[X Link](https://x.com/OzmosiHealth/status/2016577050623299655)  2026-01-28T18:20Z [----] followers, [---] engagements


"$SGMT Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40) a First-in-Class Once-Daily Oral FASN Inhibitor for Acne More Info: https://pryzm.ozmosi.com/product/15042 https://pryzm.ozmosi.com/product/15042"  
[X Link](https://x.com/OzmosiHealth/status/2016874636416602466)  2026-01-29T14:02Z [----] followers, [---] engagements


"$UNCY Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate (OLC) New Drug Application (NDA) Resubmission More Info: https://pryzm.ozmosi.com/product/33424 https://pryzm.ozmosi.com/product/33424"  
[X Link](https://x.com/OzmosiHealth/status/2016874641508487514)  2026-01-29T14:02Z [----] followers, [---] engagements


"$OSE OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab More Info: https://pryzm.ozmosi.com/product/19380 https://pryzm.ozmosi.com/product/19380"  
[X Link](https://x.com/OzmosiHealth/status/2016874650698195412)  2026-01-29T14:02Z [----] followers, [---] engagements


"$RVMD Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127 a RAS(ON) G12V-Selective Inhibitor More Info: https://pryzm.ozmosi.com/product/32673 https://pryzm.ozmosi.com/product/32673"  
[X Link](https://x.com/OzmosiHealth/status/2016874653244149950)  2026-01-29T14:02Z [----] followers, [---] engagements


"$PDSB PDS Biotech presented P2 Prostate Cancer results on 2026-01-28 for PDS-0101 More Info: https://pryzm.ozmosi.com/product/24532 https://pryzm.ozmosi.com/product/24532"  
[X Link](https://x.com/OzmosiHealth/status/2016939423334801635)  2026-01-29T18:20Z [----] followers, [---] engagements


"$AB AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer More Info: https://pryzm.ozmosi.com/product/1289 https://pryzm.ozmosi.com/product/1289"  
[X Link](https://x.com/OzmosiHealth/status/2016980255882539471)  2026-01-29T21:02Z [----] followers, [---] engagements


"$SNY Press Release: Sanofi's Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease More Info: https://pryzm.ozmosi.com/product/11397 https://pryzm.ozmosi.com/product/11397"  
[X Link](https://x.com/OzmosiHealth/status/2017237015654433229)  2026-01-30T14:02Z [----] followers, [---] engagements


"$INCY Incyte Announces Positive CHMP Opinion for Zynyz (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC) More Info: https://pryzm.ozmosi.com/product/18479 https://pryzm.ozmosi.com/product/18479"  
[X Link](https://x.com/OzmosiHealth/status/2017252017740378442)  2026-01-30T15:02Z [----] followers, [---] engagements


"$IMMP Immutep announced they will present P1 Autoimmune Disease Unspecified results in 1H26 for IMP-761 More Info: https://pryzm.ozmosi.com/product/25134 https://pryzm.ozmosi.com/product/25134"  
[X Link](https://x.com/OzmosiHealth/status/2017301818347557221)  2026-01-30T18:20Z [----] followers, [---] engagements


"$IMMP Immutep announced they will present P3 Non-Small-Cell Lung Cancer results in 1Q26 for Eftilagimod alpha More Info: https://pryzm.ozmosi.com/product/14597 https://pryzm.ozmosi.com/product/14597"  
[X Link](https://x.com/OzmosiHealth/status/2017301821254210009)  2026-01-30T18:20Z [----] followers, [---] engagements


"$KYMR Kymera Therapeutics announced they will present P2 Asthma results in 2H27 for KT-621 More Info: https://pryzm.ozmosi.com/product/32322 https://pryzm.ozmosi.com/product/32322"  
[X Link](https://x.com/OzmosiHealth/status/2017301824500621639)  2026-01-30T18:20Z [----] followers, [---] engagements


"$SGMT Sagimet presented P3 Acne Vulgaris results on 2026-01-29 for Denifanstat More Info: https://pryzm.ozmosi.com/product/15042 https://pryzm.ozmosi.com/product/15042"  
[X Link](https://x.com/OzmosiHealth/status/2017301841785348250)  2026-01-30T18:20Z [----] followers, [---] engagements


"$PHAR Pharming Group receives Complete Response Letter from U.S. FDA for sNDA for Joenja (leniolisib) in children aged [--] to [--] years with APDS More Info: https://pryzm.ozmosi.com/product/1183 https://pryzm.ozmosi.com/product/1183"  
[X Link](https://x.com/OzmosiHealth/status/2018067330140639672)  2026-02-01T21:02Z [----] followers, [---] engagements


"$SGMT +5.50% today Sagimet Announces Positive 52-Week Data from License Partner Ascletis' Open-Label Phase [--] Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne More Info: https://pryzm.ozmosi.com/product/15042 https://pryzm.ozmosi.com/product/15042"  
[X Link](https://x.com/OzmosiHealth/status/2018324102046753081)  2026-02-02T14:02Z [----] followers, [---] engagements


"$WVE -0.46% today Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency More Info: https://pryzm.ozmosi.com/product/27387 https://pryzm.ozmosi.com/product/27387"  
[X Link](https://x.com/OzmosiHealth/status/2018324104810823821)  2026-02-02T14:02Z [----] followers, [---] engagements


"$GDRX -5.60% today [--] Degrees Pharmaceuticals Expands Access to ARAKODA with GoodRx Partnership More Info: https://pryzm.ozmosi.com/product/2090 https://pryzm.ozmosi.com/product/2090"  
[X Link](https://x.com/OzmosiHealth/status/2018324110091464899)  2026-02-02T14:02Z [----] followers, [---] engagements


"$IGC -0.53% today IGC Pharma Reaches 70% Enrollment in Phase [--] CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation More Info: https://pryzm.ozmosi.com/product/25988 https://pryzm.ozmosi.com/product/25988"  
[X Link](https://x.com/OzmosiHealth/status/2018324113182597313)  2026-02-02T14:02Z [----] followers, [---] engagements


"$SNY +1.76% today Press Release: Sanofi's venglustat met all primary endpoints in a phase [--] study of type [--] Gaucher disease More Info: https://pryzm.ozmosi.com/product/8420 https://pryzm.ozmosi.com/product/8420"  
[X Link](https://x.com/OzmosiHealth/status/2018324124872155202)  2026-02-02T14:02Z [----] followers, [---] engagements


"$EXEL -2.14% today Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer More Info: https://pryzm.ozmosi.com/product/19713 https://pryzm.ozmosi.com/product/19713"  
[X Link](https://x.com/OzmosiHealth/status/2018324133520769248)  2026-02-02T14:02Z [----] followers, [---] engagements


"$PHRM PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada Building on FDA-Approved Ketamine Success More Info: https://pryzm.ozmosi.com/product/1987 https://pryzm.ozmosi.com/product/1987"  
[X Link](https://x.com/OzmosiHealth/status/2018339251214336130)  2026-02-02T15:02Z [----] followers, [---] engagements


"$RLAY +6.19% today Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant HR+/HER2- Advanced Breast Cancer More Info: https://pryzm.ozmosi.com/product/25143 https://pryzm.ozmosi.com/product/25143"  
[X Link](https://x.com/OzmosiHealth/status/2018686559432880191)  2026-02-03T14:02Z [----] followers, [---] engagements


"$MIRA -3.38% today MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase [--] Clinical Study as Company Prepares for Phase 2a Study More Info: https://pryzm.ozmosi.com/product/31932 https://pryzm.ozmosi.com/product/31932"  
[X Link](https://x.com/OzmosiHealth/status/2018686562079506708)  2026-02-03T14:02Z [----] followers, [---] engagements


"$ALLR -3.18% today Allarity Therapeutics announces that its collaborative Phase [--] trial with the United States Veteran's Administration Combining Stenoparib with Temozolomide in Relapsed Small Cell Lung Cancer is Now Open for Enrollment More Info: https://pryzm.ozmosi.com/product/19678 https://pryzm.ozmosi.com/product/19678"  
[X Link](https://x.com/OzmosiHealth/status/2018686564755517521)  2026-02-03T14:02Z [----] followers, [---] engagements


"$TOVX -0.11% today Theriva Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase [--] Clinical Trial at APAO [----] More Info: https://pryzm.ozmosi.com/product/16795 https://pryzm.ozmosi.com/product/16795"  
[X Link](https://x.com/OzmosiHealth/status/2018686567423090791)  2026-02-03T14:02Z [----] followers, [---] engagements


"$ESLA -3.14% today Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase [--] STARLIGHT-1 Data for EB103 at the [----] Tandem Meetings of ASTCT & CIBMTR More Info: https://pryzm.ozmosi.com/product/29687 https://pryzm.ozmosi.com/product/29687"  
[X Link](https://x.com/OzmosiHealth/status/2018686570069622801)  2026-02-03T14:02Z [----] followers, [---] engagements


"$FOLD -0.04% today Amicus Therapeutics Presents New Long-term Data for both Galafold (migalastat) and POMBILITI (cipaglucosidase alfa-atga) + OPFOLDA (miglustat) at the 22nd Annual WORLDSymposium [----] More Info: https://pryzm.ozmosi.com/product/5997 https://pryzm.ozmosi.com/product/5997"  
[X Link](https://x.com/OzmosiHealth/status/2018686572829573368)  2026-02-03T14:02Z [----] followers, [--] engagements


"$RARE +3.08% today Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA) More Info: https://pryzm.ozmosi.com/product/22121 https://pryzm.ozmosi.com/product/22121"  
[X Link](https://x.com/OzmosiHealth/status/2018686576155586600)  2026-02-03T14:02Z [----] followers, [--] engagements


"$ARDX +1.17% today Ardelyx Receives New Patent for Tenapanor More Info: https://pryzm.ozmosi.com/product/2151 https://pryzm.ozmosi.com/product/2151"  
[X Link](https://x.com/OzmosiHealth/status/2018686579339104444)  2026-02-03T14:02Z [----] followers, [---] engagements


"$4568 +nan% today DATROWAY Granted Priority Review in the U.S. as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy More Info: https://pryzm.ozmosi.com/product/20434 https://pryzm.ozmosi.com/product/20434"  
[X Link](https://x.com/OzmosiHealth/status/2018686585781530902)  2026-02-03T14:02Z [----] followers, [---] engagements


"$AZN +102.95% today DATROWAY (datopotamab deruxtecan-dlnk) granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy More Info: https://pryzm.ozmosi.com/product/20434 https://pryzm.ozmosi.com/product/20434"  
[X Link](https://x.com/OzmosiHealth/status/2018686588658815087)  2026-02-03T14:02Z [----] followers, [---] engagements


"$ABBV +1.22% today AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ) in Adults and Adolescents With Vitiligo More Info: https://pryzm.ozmosi.com/product/13169 https://pryzm.ozmosi.com/product/13169"  
[X Link](https://x.com/OzmosiHealth/status/2018686593977274803)  2026-02-03T14:02Z [----] followers, [---] engagements


"$SNY +0.52% today Rezurock now reimbursed in Ontario and British Columbia for people living with chronic graft-versus-host disease (GVHD) More Info: https://pryzm.ozmosi.com/product/11397 https://pryzm.ozmosi.com/product/11397"  
[X Link](https://x.com/OzmosiHealth/status/2018686597030670777)  2026-02-03T14:02Z [----] followers, [---] engagements


"$ALUR Allurion Announces Partnership to Offer Combination Therapy with Mounjaro (tirzepatide) at Discounted Prices More Info: https://pryzm.ozmosi.com/product/18435 https://pryzm.ozmosi.com/product/18435"  
[X Link](https://x.com/OzmosiHealth/status/2018701633228878187)  2026-02-03T15:02Z [----] followers, [---] engagements


"$IRD Opus Genetics announced they will present P1 Vitelliform Macular Dystrophy results on 2026-02-27 for OPGx-BEST1 More Info: https://pryzm.ozmosi.com/product/36799 https://pryzm.ozmosi.com/product/36799"  
[X Link](https://x.com/OzmosiHealth/status/2018751371261124859)  2026-02-03T18:20Z [----] followers, [---] engagements


"$SKYE Skye Bioscience announced they will present P2 Obesity results in 3Q26 for Nimacimab More Info: https://pryzm.ozmosi.com/product/19870 https://pryzm.ozmosi.com/product/19870"  
[X Link](https://x.com/OzmosiHealth/status/2018751374461374797)  2026-02-03T18:20Z [----] followers, [---] engagements


"$Private CREATE Medicines presented P0 Autoimmune Disease Unspecified results on 2026-02-02 for CRT-402 More Info: https://pryzm.ozmosi.com/product/37207 https://pryzm.ozmosi.com/product/37207"  
[X Link](https://x.com/OzmosiHealth/status/2018751377254863119)  2026-02-03T18:20Z [----] followers, [---] engagements


"$Private CREATE Medicines presented P0 Autoimmune Disease Unspecified results on 2026-02-02 for CRT-402 More Info: https://pryzm.ozmosi.com/product/37207 https://pryzm.ozmosi.com/product/37207"  
[X Link](https://x.com/OzmosiHealth/status/2018751379846885452)  2026-02-03T18:20Z [----] followers, [--] engagements


"$SKYE Skye Bioscience presented P2 Obesity results on 2026-02-02 for Nimacimab More Info: https://pryzm.ozmosi.com/product/19870 https://pryzm.ozmosi.com/product/19870"  
[X Link](https://x.com/OzmosiHealth/status/2018751382296432933)  2026-02-03T18:20Z [----] followers, [---] engagements


"$IMUX Immunic to Present Additional Phase [--] CALLIPER Trial Data for Vidofludimus Calcium at the ACTRIMS Forum [----] Reinforcing Its Potential in Progressive Multiple Sclerosis More Info: https://pryzm.ozmosi.com/product/8436 https://pryzm.ozmosi.com/product/8436"  
[X Link](https://x.com/OzmosiHealth/status/2019048967204704264)  2026-02-04T14:02Z [----] followers, [---] engagements


"$BIIB Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy More Info: https://pryzm.ozmosi.com/product/1525 https://pryzm.ozmosi.com/product/1525"  
[X Link](https://x.com/OzmosiHealth/status/2019048969738076410)  2026-02-04T14:02Z [----] followers, [---] engagements


"$TEVA Teva Canada Announces Approval of Expanded Indication of PrAJOVY (fremanezumab solution for subcutaneous injection) the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine More Info: https://pryzm.ozmosi.com/product/10812 https://pryzm.ozmosi.com/product/10812"  
[X Link](https://x.com/OzmosiHealth/status/2019048972984496131)  2026-02-04T14:02Z [----] followers, [---] engagements


"$FOLD Amicus announced they will present P2 Glycogen Storage Disease Type II results on 2026-02-05 for Migalastat More Info: https://pryzm.ozmosi.com/product/5997 https://pryzm.ozmosi.com/product/5997"  
[X Link](https://x.com/OzmosiHealth/status/2019113754584313931)  2026-02-04T18:20Z [----] followers, [--] engagements


"$ESLA Estrella announced they will present P1 Lymphoma Non-Hodgkin results on 2026-02-07 for EB-103 More Info: https://pryzm.ozmosi.com/product/29687 https://pryzm.ozmosi.com/product/29687"  
[X Link](https://x.com/OzmosiHealth/status/2019113757088387334)  2026-02-04T18:20Z [----] followers, [---] engagements


"$PFE Pfizer announced they will present P2 Obesity results on 2026-06-06 for MET-097 More Info: https://pryzm.ozmosi.com/product/33583 https://pryzm.ozmosi.com/product/33583"  
[X Link](https://x.com/OzmosiHealth/status/2019113763484627317)  2026-02-04T18:20Z [----] followers, [--] engagements


"$RLAY Relay Therapeutics announced they will present P3 Breast Cancer results on 2026-03-16 for Zovegalisib More Info: https://pryzm.ozmosi.com/product/25143 https://pryzm.ozmosi.com/product/25143"  
[X Link](https://x.com/OzmosiHealth/status/2019113766219313452)  2026-02-04T18:20Z [----] followers, [---] engagements


"$TOVX Theriva Biologics announced they will present P1 Retinoblastoma results on 2026-02-07 for Zabilugene almadenorepvec More Info: https://pryzm.ozmosi.com/product/16795 https://pryzm.ozmosi.com/product/16795"  
[X Link](https://x.com/OzmosiHealth/status/2019113768744284351)  2026-02-04T18:20Z [----] followers, [---] engagements


"$PFE Pfizer presented P2 Obesity results on 2026-02-03 for MET-097 More Info: https://pryzm.ozmosi.com/product/33583 https://pryzm.ozmosi.com/product/33583"  
[X Link](https://x.com/OzmosiHealth/status/2019113771294499024)  2026-02-04T18:20Z [----] followers, [---] engagements


"$SGMO Sangamo presented P1 Fabry Disease results on 2026-02-03 for Isaralgagene civaparvovec More Info: https://pryzm.ozmosi.com/product/22106 https://pryzm.ozmosi.com/product/22106"  
[X Link](https://x.com/OzmosiHealth/status/2019113774159130964)  2026-02-04T18:20Z [----] followers, [---] engagements


"$TOVX Theriva Biologics presented Unknown Intestinal Cancer results on 2026-02-03 for Ribaxamase More Info: https://pryzm.ozmosi.com/product/16690 https://pryzm.ozmosi.com/product/16690"  
[X Link](https://x.com/OzmosiHealth/status/2019113776633770354)  2026-02-04T18:20Z [----] followers, [---] engagements


"$RARE Ultragenyx presented Unknown Mucopolysaccharidosis III results on 2026-02-03 for Rebisufligene etisparvovec More Info: https://pryzm.ozmosi.com/product/22121 https://pryzm.ozmosi.com/product/22121"  
[X Link](https://x.com/OzmosiHealth/status/2019113779192291466)  2026-02-04T18:20Z [----] followers, [---] engagements


"$RNAZ TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138 More Info: https://pryzm.ozmosi.com/product/26544 https://pryzm.ozmosi.com/product/26544"  
[X Link](https://x.com/OzmosiHealth/status/2019411354554384477)  2026-02-05T14:02Z [----] followers, [---] engagements


"$FBLG FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia More Info: https://pryzm.ozmosi.com/product/19067 https://pryzm.ozmosi.com/product/19067"  
[X Link](https://x.com/OzmosiHealth/status/2019411357632975017)  2026-02-05T14:02Z [----] followers, [---] engagements


"$ATOS Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program More Info: https://pryzm.ozmosi.com/product/32506 https://pryzm.ozmosi.com/product/32506"  
[X Link](https://x.com/OzmosiHealth/status/2019411360405418429)  2026-02-05T14:02Z [----] followers, [---] engagements


"$ALVO Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio More Info: https://pryzm.ozmosi.com/product/8410 https://pryzm.ozmosi.com/product/8410"  
[X Link](https://x.com/OzmosiHealth/status/2019411363202998700)  2026-02-05T14:02Z [----] followers, [---] engagements


"$MIRM Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) More Info: https://pryzm.ozmosi.com/product/5770 https://pryzm.ozmosi.com/product/5770"  
[X Link](https://x.com/OzmosiHealth/status/2019411368978575831)  2026-02-05T14:02Z [----] followers, [--] engagements


"$MIRM Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) More Info: https://pryzm.ozmosi.com/product/5770 https://pryzm.ozmosi.com/product/5770"  
[X Link](https://x.com/OzmosiHealth/status/2019411371469992110)  2026-02-05T14:02Z [----] followers, [---] engagements


"$MIRM Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome More Info: https://pryzm.ozmosi.com/product/5770 https://pryzm.ozmosi.com/product/5770"  
[X Link](https://x.com/OzmosiHealth/status/2019411374095626458)  2026-02-05T14:02Z [----] followers, [---] engagements


"$MIRM Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome More Info: https://pryzm.ozmosi.com/product/5770 https://pryzm.ozmosi.com/product/5770"  
[X Link](https://x.com/OzmosiHealth/status/2019411377400774687)  2026-02-05T14:02Z [----] followers, [---] engagements


"$MRK Merck Announces Health Canada Approval of ENFLONSIA for the prevention of RSV in newborns and infants More Info: https://pryzm.ozmosi.com/product/19724 https://pryzm.ozmosi.com/product/19724"  
[X Link](https://x.com/OzmosiHealth/status/2019411380433260695)  2026-02-05T14:02Z [----] followers, [---] engagements


"$HIMS +10.12% today Hims & Hers Expands Personalized Weight Loss Portfolio with Access to Compounded Semaglutide Pills Starting at $49/Month* More Info: https://pryzm.ozmosi.com/product/1987 https://pryzm.ozmosi.com/product/1987"  
[X Link](https://x.com/OzmosiHealth/status/2019426332057432259)  2026-02-05T15:02Z [----] followers, [---] engagements


"$CERO CERo Therapeutics announced they will present P1 Acute Myeloid Leukemia results on 2026-02-05 for CER-1236 More Info: https://pryzm.ozmosi.com/product/30722 https://pryzm.ozmosi.com/product/30722"  
[X Link](https://x.com/OzmosiHealth/status/2019476140705083630)  2026-02-05T18:20Z [----] followers, [--] engagements


"$CRBU Caribou Biosciences announced they will present P1 Lymphoma Non-HodgkinLymphoma B-Cell results on 2026-02-05 for Vispacabtagene regedleucel More Info: https://pryzm.ozmosi.com/product/22257 https://pryzm.ozmosi.com/product/22257"  
[X Link](https://x.com/OzmosiHealth/status/2019476143737565494)  2026-02-05T18:20Z [----] followers, [---] engagements


"$CRBU Caribou Biosciences announced they will present P1 Multiple Myeloma results on 2026-02-07 for CB-011 More Info: https://pryzm.ozmosi.com/product/26508 https://pryzm.ozmosi.com/product/26508"  
[X Link](https://x.com/OzmosiHealth/status/2019476146665189738)  2026-02-05T18:20Z [----] followers, [---] engagements


"$IMUX Immunic announced they will present P2 Multiple Sclerosis Progressive results on 2026-02-05 for Vidofludimus More Info: https://pryzm.ozmosi.com/product/8436 https://pryzm.ozmosi.com/product/8436"  
[X Link](https://x.com/OzmosiHealth/status/2019476150003929508)  2026-02-05T18:20Z [----] followers, [---] engagements


"$KOD Kodiak Sciences announced they will present P1 Macular Edema results on 2026-02-07 for Tabirafusp alfa More Info: https://pryzm.ozmosi.com/product/34569 https://pryzm.ozmosi.com/product/34569"  
[X Link](https://x.com/OzmosiHealth/status/2019476152591757722)  2026-02-05T18:20Z [----] followers, [---] engagements


"$VSTM Verastem announced they will present P1 Non-Small-Cell Lung CancerPancreatic Ductal CarcinomaColorectal Cancer results in 1H26 for VS-7375 More Info: https://pryzm.ozmosi.com/product/32027 https://pryzm.ozmosi.com/product/32027"  
[X Link](https://x.com/OzmosiHealth/status/2019476155255107953)  2026-02-05T18:20Z [----] followers, [---] engagements


"$VSTM Verastem announced they will present P2 Pancreatic Ductal Carcinoma results in 2Q26 for Avutometinib More Info: https://pryzm.ozmosi.com/product/21724 https://pryzm.ozmosi.com/product/21724"  
[X Link](https://x.com/OzmosiHealth/status/2019476157964644853)  2026-02-05T18:20Z [----] followers, [---] engagements


"$VSTM Verastem announced they will present P2 Pancreatic Ductal Carcinoma results in 2Q26 for Defactinib More Info: https://pryzm.ozmosi.com/product/562 https://pryzm.ozmosi.com/product/562"  
[X Link](https://x.com/OzmosiHealth/status/2019476160548335937)  2026-02-05T18:20Z [----] followers, [---] engagements


"$BIIB Biogen presented P3 Muscular Atrophy Spinal results on 2026-02-04 for Nusinersen More Info: https://pryzm.ozmosi.com/product/1525 https://pryzm.ozmosi.com/product/1525"  
[X Link](https://x.com/OzmosiHealth/status/2019476163228495989)  2026-02-05T18:20Z [----] followers, [---] engagements


"$BAYRY Bayer's Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack With No Increase in ISTH Major Bleeding Versus Placebo More Info: https://pryzm.ozmosi.com/product/22569 https://pryzm.ozmosi.com/product/22569"  
[X Link](https://x.com/OzmosiHealth/status/2019517017456599136)  2026-02-05T21:02Z [----] followers, [---] engagements


"$ROIV Roivant Announces Positive Phase [--] Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December [--] [----] More Info: https://pryzm.ozmosi.com/product/19843 https://pryzm.ozmosi.com/product/19843"  
[X Link](https://x.com/OzmosiHealth/status/2019773634953560517)  2026-02-06T14:02Z [----] followers, [---] engagements


"$ROIV Roivant Announces Positive Phase [--] Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December [--] [----] More Info: https://pryzm.ozmosi.com/product/19843 https://pryzm.ozmosi.com/product/19843"  
[X Link](https://x.com/OzmosiHealth/status/2019773637650452497)  2026-02-06T14:02Z [----] followers, [---] engagements


"$ROIV Priovant Announces Positive Phase [--] Results for Brepocitinib in Cutaneous Sarcoidosis (CS) More Info: https://pryzm.ozmosi.com/product/19843 https://pryzm.ozmosi.com/product/19843"  
[X Link](https://x.com/OzmosiHealth/status/2019773640724959238)  2026-02-06T14:02Z [----] followers, [---] engagements


"$ROIV Priovant Announces Positive Phase [--] Results for Brepocitinib in Cutaneous Sarcoidosis (CS) More Info: https://pryzm.ozmosi.com/product/19843 https://pryzm.ozmosi.com/product/19843"  
[X Link](https://x.com/OzmosiHealth/status/2019773643497361832)  2026-02-06T14:02Z [----] followers, [---] engagements


"$TGTX TG Therapeutics Announces Presentation of Data for BRIUMVI (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum More Info: https://pryzm.ozmosi.com/product/8349 https://pryzm.ozmosi.com/product/8349"  
[X Link](https://x.com/OzmosiHealth/status/2019773646823399805)  2026-02-06T14:02Z [----] followers, [---] engagements


"$GILD FDA Approves Label Update for Kite's Yescarta for Relapsed/Refractory Primary Central Nervous System Lymphoma More Info: https://pryzm.ozmosi.com/product/15391 https://pryzm.ozmosi.com/product/15391"  
[X Link](https://x.com/OzmosiHealth/status/2019773650057245068)  2026-02-06T14:02Z [----] followers, [---] engagements


"$PFE FDA Grants Priority Review for HYMPAVZI (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need More Info: https://pryzm.ozmosi.com/product/15024 https://pryzm.ozmosi.com/product/15024"  
[X Link](https://x.com/OzmosiHealth/status/2019773652917735445)  2026-02-06T14:02Z [----] followers, [---] engagements


"$BRCTF Sales of Leqembi totaled [----] billion yen in the fourth quarter [----] More Info: https://pryzm.ozmosi.com/product/16901 https://pryzm.ozmosi.com/product/16901"  
[X Link](https://x.com/OzmosiHealth/status/2019773658865324134)  2026-02-06T14:02Z [----] followers, [---] engagements


"$AIM AIM presented P2 Pancreatic Cancer results on 2026-02-05 for Rintatolimod More Info: https://pryzm.ozmosi.com/product/7277 https://pryzm.ozmosi.com/product/7277"  
[X Link](https://x.com/OzmosiHealth/status/2019838528339996804)  2026-02-06T18:20Z [----] followers, [---] engagements


"$ASND Pendopharm Announces the Approval of Yorvipath (palopegteriparatide injection) for the Treatment of Chronic Hypoparathyroidism in Adults More Info: https://pryzm.ozmosi.com/product/32243 https://pryzm.ozmosi.com/product/32243"  
[X Link](https://x.com/OzmosiHealth/status/2019879317438885953)  2026-02-06T21:02Z [----] followers, [---] engagements


"$RHHBY Roche's fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS) More Info: https://pryzm.ozmosi.com/product/12578 https://pryzm.ozmosi.com/product/12578"  
[X Link](https://x.com/OzmosiHealth/status/2020241731007246709)  2026-02-07T21:02Z [----] followers, [---] engagements


"$RHHBY Roche's fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS) More Info: https://pryzm.ozmosi.com/product/12578 https://pryzm.ozmosi.com/product/12578"  
[X Link](https://x.com/OzmosiHealth/status/2020241733620314466)  2026-02-07T21:02Z [----] followers, [---] engagements


"$RHHBY Genentech's Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS) More Info: https://pryzm.ozmosi.com/product/12578 https://pryzm.ozmosi.com/product/12578"  
[X Link](https://x.com/OzmosiHealth/status/2020241736124313934)  2026-02-07T21:02Z [----] followers, [---] engagements


"$RHHBY Genentech's Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS) More Info: https://pryzm.ozmosi.com/product/12578 https://pryzm.ozmosi.com/product/12578"  
[X Link](https://x.com/OzmosiHealth/status/2020241738401820842)  2026-02-07T21:02Z [----] followers, [---] engagements


"$MANE Veradermics Completes Enrollment in Second Pivotal Phase [--] Clinical Trial of VDPHL01 for Male Pattern Hair Loss More Info: https://pryzm.ozmosi.com/product/33162 https://pryzm.ozmosi.com/product/33162"  
[X Link](https://x.com/OzmosiHealth/status/2020860943916552269)  2026-02-09T14:02Z [----] followers, [---] engagements


"$FDMT 4DMT Completes Enrollment for 4FRONT-1 Phase [--] Clinical Trial of 4D-150 in Wet AMD More Info: https://pryzm.ozmosi.com/product/27134 https://pryzm.ozmosi.com/product/27134"  
[X Link](https://x.com/OzmosiHealth/status/2020860946735087952)  2026-02-09T14:02Z [----] followers, [--] engagements


"$CMND Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial More Info: https://pryzm.ozmosi.com/product/27783 https://pryzm.ozmosi.com/product/27783"  
[X Link](https://x.com/OzmosiHealth/status/2020860952439312759)  2026-02-09T14:02Z [----] followers, [---] engagements


"$CANF Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy More Info: https://pryzm.ozmosi.com/product/19867 https://pryzm.ozmosi.com/product/19867"  
[X Link](https://x.com/OzmosiHealth/status/2020860958172946796)  2026-02-09T14:02Z [----] followers, [--] engagements


"$SNY Press Release: Sanofi's rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia More Info: https://pryzm.ozmosi.com/product/18646 https://pryzm.ozmosi.com/product/18646"  
[X Link](https://x.com/OzmosiHealth/status/2020860963583615334)  2026-02-09T14:02Z [----] followers, [---] engagements


"$ESLA Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the [----] Tandem Meetings of ASTCT & CIBMTR More Info: https://pryzm.ozmosi.com/product/29687 https://pryzm.ozmosi.com/product/29687"  
[X Link](https://x.com/OzmosiHealth/status/2020860966171521503)  2026-02-09T14:02Z [----] followers, [---] engagements


"$NUVB Nuvation Bio Announces Pivotal Global Phase [--] SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma More Info: https://pryzm.ozmosi.com/product/22745 https://pryzm.ozmosi.com/product/22745"  
[X Link](https://x.com/OzmosiHealth/status/2020860969212334197)  2026-02-09T14:02Z [----] followers, [---] engagements


"$BRCTF BLA for subcutaneous formulation of Leqembi designated for Priority Review in China More Info: https://pryzm.ozmosi.com/product/16901 https://pryzm.ozmosi.com/product/16901"  
[X Link](https://x.com/OzmosiHealth/status/2020860974593683678)  2026-02-09T14:02Z [----] followers, [---] engagements


"$NRSN NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition More Info: https://pryzm.ozmosi.com/product/28154 https://pryzm.ozmosi.com/product/28154"  
[X Link](https://x.com/OzmosiHealth/status/2020876041200525804)  2026-02-09T15:02Z [----] followers, [---] engagements


"$AMLX Positive long-term results from Phase [--] HELIOS trial of AMX0035 in Wolfram syndrome announced by Amylyx Pharmaceuticals. More Info: $XBI $IBB $XPH $PPH https://pryzm.ozmosi.com/product/14195 https://pryzm.ozmosi.com/product/14195"  
[X Link](https://x.com/OzmosiHealth/status/1921891247905816948)  2025-05-12T11:32Z [----] followers, [---] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing